



# Shanghai Bao Pharmaceuticals Co., Ltd.

上海寶濟藥業股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(於中華人民共和國成立的股份有限公司)

(Stock Code 股份代號 : 2659)

16 January 2026

Dear registered shareholder(s),

## Arrangement of Electronic Dissemination of Corporate Communications

Pursuant to Rule 2.07A of the Rules Governing The Listing of Securities on The Stock Exchange of Hong Kong Limited under the expansion of paperless listing regime and electronic dissemination of corporate communications that came into effect on 31 December 2023, Shanghai Bao Pharmaceuticals Co., Ltd. (the "Company") is writing to inform you that the Company has adopted electronic dissemination of corporate communications (the "Corporate Communications"), which mean any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.

Please note that both the English and Chinese versions of all future Corporate Communications will be available electronically on the website of the Company at [www.baopharma.com](http://www.baopharma.com) and the HKEXnews website at [www.hkexnews.hk](http://www.hkexnews.hk) in place of printed copies.

### Solicitation of electronic contact details

To ensure timely receipt of the Actionable Corporate Communications<sup>(Note)</sup>, the Company recommends you provide your email address by scanning your personalized QR code printed on the enclosed reply form (the "Reply Form"). Alternatively, you may sign and return the Reply Form to the Company's H share registrar (the "H Share Registrar"), Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong.

If the Company does not receive a functional email address in your reply, until such time that the functional email address is provided to the H Share Registrar, you (i) need to proactively check the Company's website and the HKEXnews website to keep up with the publication of Corporate Communications; and (ii) the Company will send the Actionable Corporate Communications<sup>(Note)</sup> in printed form in the future.

If you want to receive the future Corporate Communications in printed form, please complete and return the Reply Form to the H Share Registrar or send an email to [Baopharma.ecom@computershare.com.hk](mailto:Baopharma.ecom@computershare.com.hk) specifying your name, address and request to receive the Corporate Communications in printed form. Please note that such instruction shall be valid for one year starting from the receipt date of your instruction and will expire thereafter.

Should you have any queries relating to this letter, please contact the H Share Registrar by sending an email to [Baopharma.ecom@computershare.com.hk](mailto:Baopharma.ecom@computershare.com.hk).

Yours faithfully,  
By order of the Board  
**Shanghai Bao Pharmaceuticals Co., Ltd.**  
**Dr. Liu Yanjun**  
Chairman of the Board and Executive Director

*Note: Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.*

各位登記股東：

## 以電子方式發佈公司通訊之安排

根據自 2023 年 12 月 31 日起生效的擴大無紙化上市機制及以電子方式發佈公司通訊規定下香港聯合交易所有限公司證券上市規則第 2.07A 條，上海寶濟藥業股份有限公司（「本公司」）謹此通知 閣下，本公司已採用以電子方式發佈公司通訊（「公司通訊」）之安排，該公司通訊是指本公司為向其任何證券持有人提供資訊或提醒其採取行動而發佈或將要發佈的任何文件，包括但不限於(a) 董事報告、年度帳目以及審計報告副本以及（如適用）財務摘要報告；(b) 中期報告及其中期報告摘要（如適用）；(c) 會議通知；(d) 上市文件；(e) 通函和 (f) 委任表格。

請注意，所有日後公司通訊的英文版和中文版將在本公司網站 [www.baopharma.com](http://www.baopharma.com) 和披露易網站 [www.hkexnews.hk](http://www.hkexnews.hk) 上提供，以代替印刷本。

### 徵集電子聯絡資料

為確保及時收到可供採取行動的公司通訊<sup>(附註)</sup>，本公司建議 閣下透過掃描本函隨附之回條（「回條」）上列印的 閣下專屬二維碼來提供 閣下的電子郵件地址。或者， 閣下也可以簽署回條並交回本公司的 H 股股份過戶登記處（「H 股股份過戶登記處」）香港中央證券登記有限公司，地址為香港灣仔皇后大道東 183 號合和中心 17M 樓。

如果本公司沒有收到 閣下的有效電子郵件地址，直至 H 股股份過戶登記處收到 閣下有效的電子郵件地址前， 閣下(i)需要主動查看本公司網站和披露易網站以留意公司通訊的發佈；及(ii)本公司未來將以印刷本形式發送可供採取行動的公司通訊<sup>(附註)</sup>。

若 閣下希望收取日後公司通訊之印刷本，請填妥回條並交予 H 股股份過戶登記處，或發送電子郵件至 [Baopharma.ecom@computershare.com.hk](mailto:Baopharma.ecom@computershare.com.hk)，並註明 閣下的姓名、地址以及收取公司通訊印刷本的要求。請注意，收取日後公司通訊印刷本之指示由收悉 閣下指示當日起計一年內有效，此後將告失效。

如 閣下對本函件有任何疑問，請發送電子郵件至 [Baopharma.ecom@computershare.com.hk](mailto:Baopharma.ecom@computershare.com.hk) 向 H 股股份過戶登記處查詢。

承董事會命  
**上海寶濟藥業股份有限公司**  
董事長兼執行董事  
**劉彥君博士**  
謹啟

2026 年 1 月 16 日

附註：可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使有關證券持有人的權利或作出選擇的公司通訊。

## REPLY FORM 回條

To: Computershare Hong Kong Investor Services Limited  
 (the "H Share Registrar")  
 17M Floor, Hopewell Centre  
 183 Queen's Road East, Wan Chai, Hong Kong

致: 香港中央證券登記有限公司  
 (「H股股份過戶登記處」)  
 香港灣仔皇后大道東 183 號  
 合和中心 17M 樓

(Please choose ONLY ONE of the options below)  
 (請從以下選項中只選擇其中一項)

Personalized QR Code  
 專屬二維碼

**Option 1:** Provide your email address for receipt of future Actionable Corporate Communications<sup>(Note 3)</sup> of the Company via electronic dissemination by scanning your personalized QR code

**選項 1:** 掃瞄 閣下專屬二維碼提供 閣下之電子郵件地址，以接收本公司日後通過電子方式發佈的可供採取行動的公司通訊<sup>(附註 3)</sup>

You are NOT required to return this Reply Form if you choose Option 1.  
 如選擇了選項 1， 閣下無須交回本回條。

**Option 2:** I/we hereby provide my/our email address in writing for receipt of future Actionable Corporate Communications<sup>(Note 3)</sup> of the following listed company (the "Company") via electronic dissemination

**選項 2:** 本人/吾等現以書面提供本人/吾等之的電子郵件地址，以確保收到以下上市公司（「本公司」）日後通過電子方式發佈的可供採取行動的公司通訊<sup>(附註 3)</sup>

Name of Securities holder(s) 證券持有人姓名:

Name of the listed company 上市公司名稱:

Shanghai Bao Pharmaceuticals Co., Ltd.  
 上海寶濟藥業股份有限公司

Email address 電郵地址: (Notes 3 / 附註 3)

**Option 3:** I/we hereby request for receipt of Corporate Communications\* in printed form (Please mark "✓" in the below box if applicable)

**選項 3:** 本人/吾等現要求收取公司通訊\*印刷本（如適用，請在下方格內劃上「✓」號）

receive the future Corporate Communications\* in printed copy and noted that this instruction is valid only for one year starting from the receipt date of instruction. (Notes 5)  
 收取日後公司通訊\*的印刷本，並已知悉本指示由收取指示日期起計一年內有效。（附註 5）

Signature(s): (Notes 1)

簽名: (附註 1)

Contact number:

聯絡電話號碼:

Date:

日期:

Notes 附註:

- Please complete all your details clearly. If your shares are held in joint names, all of the joint shareholders should jointly sign this Reply Form in order to be valid.  
 請清楚填妥 閣下所有資料，如屬聯名股東，則本回條須由所有聯名股東聯合簽署，方為有效。
- Any Reply Form with no signature or otherwise incorrectly completed will be void.  
 任何回條若未有簽署或在其他方面填寫不正確，則本回條將會作廢。
- If the Company does not receive a functional email address in your reply, the Company will send the Actionable Corporate Communication in printed form in the future. Actionable Corporate Communication is any corporate communication that seeks instructions from issuer's securities holders on how they wish to exercise their rights or make an election as the issuer's securities holder.  
 如本公司沒有收到 閣下的有效電子郵件地址，本公司日後將以印刷形式發送可供採取行動的公司通訊，可供採取行動的公司通訊指任何涉及要求發行人的證券持有人指示其擬如何行使有關證券持有人的權利的公司通訊。
- If you provide more than one email address by QR code, email, Reply Form and/or other means, only the latest one email address provided will be registered.  
 如 閣下通過二維碼、電郵、回條及/或其他方式提供多於一個的電子郵件地址，只有 閣下最後提供的電子郵件地址將會被用於登記。
- If you mark "✓" in the box in Option 3, no email address will be registered and only Corporate Communications\* in printed form will be received.  
 如 閣下在選項 3 方格內劃上「✓」號，將不會有電子郵件地址被登記，只會收取公司通訊\*的印刷本。
- For the avoidance of doubt, the Company does not accept any other instructions given on this Reply Form.  
 為免疑慮，在本回條上的任何額外指示，本公司將不予以理。

\* Unless otherwise specified, Corporate Communications refer to any documents issued or to be issued by the Company for the information or action of holders of any of its securities, including but not limited to (a) the directors' report, its annual accounts together with a copy of the auditors' report and, where applicable, its summary financial report; (b) the interim report and, where applicable, its summary interim report; (c) a notice of meeting; (d) a listing document; (e) a circular and (f) a proxy form.  
 除非另有註明，公司通訊指本公司已發出或將發出以其任何證券的持有人參照或採取行動的任何文件，其中包括但不限於(a)董事報告、年度賬目以及審計報告副本以及（如適用）財務摘要報告；(b)中期報告及其中期報告摘要（如適用）；(c)會議通告；(d)上市文件；(e)通函及 (f)委任表格。

PERSONAL INFORMATION COLLECTION STATEMENT 收集個人資料聲明

- "Personal Data" this statement has the same meaning as "personal data" in the Personal Data (Privacy) Ordinance, Chapter 486 of the Laws of Hong Kong ("PDPO").  
 本聲明中所指的「個人資料」與香港法例第 486 章（個人資料（私隱）條例）（「《私隱條例》」）中「個人資料」的涵義相同。
- Your Personal Data provided in this Reply Form will be used in connection with, including but not limited to, the Company's electronic dissemination of Corporate Communications\* and to liaise with you on other matters relating to your holdings in the Company. Your supply of Personal Data to the Company is on a voluntary basis. In case of a failure to provide sufficient information, the Company may not be able to process your instruction and/or request as stated in this Reply Form.  
 閣下所提供的個人資料將用於（包括但不限於）有關本公司以電子方式發佈公司通訊\*及就 閣下持有的公司證券有關的其他事宜上與 閣下聯絡。 閣下是自願向本公司提供個人資料。若 閣下未能提供足夠資料，本公司可能無法處理 閣下在本回條上所提出的指示或要求。
- Your Personal Data may be disclosed or transferred by the Company to its subsidiaries, the H Share Registrar, and/or other companies or bodies for any of the stated purposes, or when it is required to do so by law and will be retained for such period as may be necessary for our verification and record purposes.  
 本公司可就任何所說明的用途或在法例規定的情況下，將 閣下的個人資料披露或轉移給本公司的附屬公司、H股股份過戶登記處、及/或其他公司或團體，並將在適當期間保留該個人資料以核實及紀錄用途。
- You have the right to request access to and/or correction of your Personal Data in accordance with the provisions of the PDPO. Any such request for access to and/or correction of your Personal Data should be in writing, by mail to the Hong Kong Privacy Officer of the H Share Registrar at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong or by email at [PrivacyOfficer@computershare.com.hk](mailto:PrivacyOfficer@computershare.com.hk).  
 閣下有權根據《私隱條例》的條文查閱及/或修改 閣下的個人資料。任何該等查閱及/或修改個人資料的要求均須以書面方式寄至 H 股份過戶登記處（地址為香港灣仔皇后大道東 183 號合和中心 17M 樓）向香港隱私主任提出，或發送電郵至 [PrivacyOfficer@computershare.com.hk](mailto:PrivacyOfficer@computershare.com.hk)。

Mailing Label 郵寄標籤

Computershare Hong Kong Investor Services Limited

香港中央證券登記有限公司

Freepost No. 雜便回郵號碼: 37

Hong Kong 香港

Please cut the mailing label and stick it on an envelope to return this form to us.

No postage is necessary if posted in Hong Kong.

當 閣下寄回此回條時，請將郵寄標籤剪貼於信封上。

如在本港投寄， 閣下無須支付郵費或貼上郵票。